mTOR in viral hepatitis and hepatocellular carcinoma: function and treatment. - Wikidata - awgldk - TriplyDB

mTOR in viral hepatitis and hepatocellular carcinoma: function and treatment.

mTOR in viral hepatitis and hepatocellular carcinoma: function and treatment.

http://www.wikidata.org/entity/Q41233635

about

Hepatocellular carcinoma and hepatitis B surface protein Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival Simple sugar intake and hepatocellular carcinoma: epidemiological and mechanistic insight Hepatitis B virus molecular biology and pathogenesis Activation of ATP citrate lyase by mTOR signal induces disturbed lipid metabolism in hepatitis B virus pre-S2 mutant tumorigenesis.Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer Hepatitis D and hepatocellular carcinoma.The circular RNA ciRS-7 (Cdr1as) acts as a risk factor of hepatic microvascular invasion in hepatocellular carcinoma.Inhibition of autophagy potentiates the proliferation inhibition activity of microRNA-7 in human hepatocellular carcinoma cells.Simvastatin and metformin inhibit cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy.LXRɑ participates in the mTOR/S6K1/SREBP-1c signaling pathway during sodium palmitate-induced lipogenesis in HepG2 cells.

P2860

Q26766123-3C3AA812-F4E4-4BCE-B1FB-488A47969B49 Q26853543-A245417D-88AC-4617-9CF9-6D5EDC551A9A Q26864513-2B49C8A8-F881-4FB7-81F5-F25C9AF8E033 Q28818406-077E1B56-F6C8-4A74-BE7D-1399B793BA3F Q34992761-127902A5-01EB-45DB-9D98-3F678EB7AA55 Q36167088-5C7F2CB2-ED42-4C8F-924E-A459E0C1E1FC Q38443653-23411126-DE15-48E4-896A-E1E9173A0FA3 Q39403970-895689F7-2BA1-4E09-AA85-A468E4FF1D1D Q41616170-2BA29CC5-55B5-46F7-85CA-5114553E342A Q47547628-C422A7E4-BD98-4564-8D16-6CE551A85D9E Q54945090-A976939C-6A70-4DE6-8392-EEE8433998AB

P2860

mTOR in viral hepatitis and hepatocellular carcinoma: function and treatment.

http://www.wikidata.org/entity/Q41233635

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

mTOR in viral hepatitis and hepatocellular carcinoma: function and treatment.

@en

type

label

mTOR in viral hepatitis and hepatocellular carcinoma: function and treatment.

@en

prefLabel

mTOR in viral hepatitis and hepatocellular carcinoma: function and treatment.

@en

P1433

Q41233635-932BA77D-140D-445E-B5DF-0600FDB6273F

P1476

Q41233635-FF353BCE-867A-487F-AE52-363650537501

P2093

Q41233635-3ACDB1DB-9BCE-423F-B828-612ACBF8079B

Q41233635-A53AB34A-652D-4024-8E8B-D6D153743391

Q41233635-D4C6E33B-210C-4963-8DAB-2DD53F01D13E

Q41233635-E59227DB-3BA5-44B7-AABF-1CF8BCEE5934

P275

Q41233635-61437CBA-635F-45EA-88B6-B9B1A13A6418

P2860

Q41233635-00765BC0-62FC-4A69-AED1-C07630D2DBDB

Q41233635-0366B10F-9656-4E77-9B54-F78CC4E55E48

Q41233635-063B5258-32B2-455E-BD93-E7D7A8BA2F5B

Q41233635-0DAD34B8-B31E-47A2-90EF-1012DC878565

Q41233635-104BC062-F30B-45D8-8CAC-122460B90100

Q41233635-12E765BA-B0CC-46CB-8186-FF2F3B517B1C

Q41233635-139B0271-1521-4C70-9A76-64D238B0375A

Q41233635-1904F0F8-4437-4E7E-94A6-DB42C4DE6698

Q41233635-1EB217A8-BD04-436F-A99C-BB23E69B1D9D

Q41233635-2308CF13-FDD0-4F3B-8EFF-569249B040F5

P304

Q41233635-282F12ED-5465-4055-A2AE-CCD8F6C9A4E5

P31

Q41233635-510E0768-5FDA-4EC9-9F20-055ACFF66275

Q41233635-633B623F-E044-4499-8620-1CC281BCCA19

P356

Q41233635-BE4D6EA0-2370-4C17-9A6C-8C7853705335

P407

Q41233635-AA17461B-CBCD-4289-890F-5BE6EA893DC1

P478

Q41233635-9F4604C9-D64F-4E35-A8DC-C8BDDD2A4B5F

P5008

Q41233635-3133DF6A-55E0-420A-A07D-6269E83309DE

P577

Q41233635-4484BA29-7A07-463E-B650-2FC68C6CF308

P5875

Q41233635-4CDCC5A0-B783-4C56-9C70-26CD3FF52135

P698

Q41233635-CD0D6233-8D34-43BE-B1D8-16D158A313C0

P921

Q41233635-151C4C63-A866-4876-BB4A-EA04AC122B5A

Q41233635-6CFA7C23-F5BB-47E7-9140-5E185EF15AF8

Q41233635-A68D60E4-066F-4726-AAA0-8090551BFBF7

Q41233635-AB8EA357-FB00-434A-B811-F3D6A15AE055

Q41233635-C45DEFE5-2E80-4385-A70D-5E8C242FDBE5

P932

Q41233635-3A894919-B8C6-4755-B161-AA52F8F19781

P356

P1433

BioMed Research International

P1476

mTOR in viral hepatitis and hepatocellular carcinoma: function and treatment.

@en

P2093

Hongchuan Jin

http://www.w3.org/2001/XMLSchema#string

Wei Jin

http://www.w3.org/2001/XMLSchema#string

Xian Wang

http://www.w3.org/2001/XMLSchema#string

Zhuo Wang

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 3.0 Unported

P2860

Hepatitis C virus non-structural protein NS5A interacts with FKBP38 and inhibits apoptosis in Huh7 hepatoma cells

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth

Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control

The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1

Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene

P304

735672

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2014/735672

http://www.w3.org/2001/XMLSchema#string

P407

P478

2014

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2014-04-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262113706

http://www.w3.org/2001/XMLSchema#string

P698

24804240

http://www.w3.org/2001/XMLSchema#string

P921

hepatocellular carcinoma

mechanism of action

P932

3996896

http://www.w3.org/2001/XMLSchema#string